IN8bio, Inc. - Bathi saben saham sajrone rolas wulan pungkasan INAB

The development of IN8bio, Inc. (INAB) relies on the safety and recognition of brain and blood oncology treatments. The rolling trailing twelve-month earnings per share shows a pivot driven by the outsourcing of trials to external centers and the implementation of innovative gamma-delta T-cell therapy. The value of -1.24 reflects this status, confirming the company's current level of financial stability on this chart.

INAB Bathi resik saben siji saham sajrone rolas wulan pungkasan IN8bio Inc (04.07.2022 - 14.11.2026)

Rincian metrik lan analitis perusahaan IN8bio Inc (INAB)

- kuotasi saiki lan rata-rata prakiraan nilai:

Bagan rega IN8bio|INAB - Bagan rega target

- rincian nilai pasar emiten:

Nilai pasar IN8bio, Inc.|INAB - Total Nilai Perusahaan

- data nilai buku modal saham:

Aset Bersih saben Siji Saham IN8bio|INAB - Ekuitas Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku in8bio.com|INAB - Total Aset Bisnis

- rincian utang lan likuiditas:

- data bathi lan kelipatan valuasi:

INAB - Bathi resik perusahaan|Bathi resik sing dikarepake IN8bio, Inc.|INAB - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi IN8bio Inc.|INAB - Pangali PEG|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan IN8bio, Inc|INAB - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajrone 12 wulan pungkasan IN8bio|INAB - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan in8bio.com|INAB - Wutah bathi resik saben saham ing taun iki|Prakiraan konsensus wutah bathi saben saham kanggo taun ngarep IN8bio, Inc.

- data pendapatan lan penerimaan dodolan:

INAB - Pendapatan lan volume dodolan|Dodolan mangsa ngarep perusahaan IN8bio|INAB - Rasio rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan IN8bio Inc.

Pambiji fundamental:INAB in8bio.com

Developing cancer cell therapy requires the management of IN8bio, Inc. (INAB) to maintain maximum efficiency in resource allocation. The EPS TTM metric measures the final profit allocated per security, excluding distortions caused by changes in the volume of issuance. For the investor, this calculation serves as a filter for the business's real yield. Analyzing the net income per share over the last 12 months allows for an assessment of the biotech's financial stability. The price action on this chart determines the fundamental value of a stake in the company.

Pesaing IN8bio, Inc. (INAB)